United Therapeutics' clinical trial represents a significant advancement in addressing the organ shortage crisis and improving the survival and quality of life for ESRD patients.

After years of research into xenotransplantation, the field is at a turning point—yet risks and ethical issues remain ...

United Therapeutics in downtown Silver Spring has received regulatory approval to begin clinical trials for pig-to-human kidney transplants. The Food and Drug Administration has granted the ...

From the Washington Business Journal. United Therapeutics Corp. (NASDAQ: UTHR) has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to be ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

It's early days for xenotransplantation, but eGenesis, Eledon, United Therapeutics and more are working to develop solutions ...

Building a climate-controlled warehouse and logistics facility for United Therapeutics in North Carolina’s Research Triangle was a matter of power management and careful planning. The facility ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales.

This transplant builds on two successful UHeart™ transplants completed in 2022 and 2023 and a successful UThymoKidney™ transplant in 2024 United Therapeutics Corporation (Nasdaq: UTHR), a ...

United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 04, 2025--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James ...